Nectar Lifesciences Holds EGM: Key Resolutions on Director Appointment and Business Transfer Aug 04, 2025
More news about Nectar Lifesciences
08Jul 25
Nectar Lifesciences to Divest Key Businesses for ₹1,290 Crore
Nectar Lifesciences plans to sell its API, Formulations, and Menthol businesses to Ceph Lifesciences for ₹1,290 crore. The deal is expected to complete by September 20, 2025, subject to approvals. Proceeds will be used for debt repayment, new investments, and shareholder rewards. An EGM is scheduled for August 4, 2025, to seek shareholder approval.
08Jul 25
Nectar Lifesciences Reports Q4 Revenue Decline and Significant Loss
Nectar Lifesciences' Q4 financial results show a 2.28% year-on-year revenue decline to ₹4.29 billion. The company reported a significant loss of ₹576 million, compared to a profit of ₹105 million in the same quarter last year, marking a 648.57% negative swing in the bottom line.
30Apr 25
Nectar Lifesciences Secures 2-Year GMP Certification from Brazil's ANVISA for Key APIs
Nectar Lifesciences Limited's Unit II in Punjab has received a two-year Good Manufacturing Practice (GMP) certification from Brazil's ANVISA for two Active Pharmaceutical Ingredients: Ceftazidime pentahydrate and Ceftriaxone disodium hemiheptahydrate. The certification, valid from April 28, 2025, covers chemical synthesis and sterilization processes, validating the company's manufacturing standards and potentially opening new opportunities in the Brazilian market.
10Mar 25
Nectar Lifesciences' API Facility Faces Critical Observations in Joint European Inspection
Nectar Lifesciences' API manufacturing facility in Punjab, India, received seven observations, including four critical ones, during a joint inspection by EDQM and AEMPS. The company is preparing a CAPA report and will undergo a re-inspection for EuGMP approval. CEO Amit Chadah reaffirmed the company's commitment to quality and compliance standards.